Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.

Li, Ang; Manohar, Poorni M; Garcia, David A; Lyman, Gary H; Steuten, Lotte M

Li, Ang; Manohar, Poorni M; Garcia, David A; Lyman, Gary H; Steuten, Lotte M.

Affiliation

Li A; Division of Hematology, University of Washington School of Medicine, Seattle, WA, United States of America. Electronic address: ali2015@uw.edu.
Manohar PM; Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, United States of America.
Garcia DA; Division of Hematology, University of Washington School of Medicine, Seattle, WA, United States of America.
Lyman GH; Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, United States of America; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Steuten LM; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.

Thromb Res ; 180: 37-42, 2019 Aug.

Article in En | MEDLINE | ID: mdl-31200341

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Thiazoles / Thrombosis / Dalteparin / Factor Xa Inhibitors / Rivaroxaban / Anticoagulants Type of study: Etiology_studies / Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Systematic_reviews Aspects: Patient_preference Limits: Humans Language: En Journal: Thromb Res Year: 2019 Document type: Article Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google